X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (30) 30
humans (25) 25
aged (23) 23
female (21) 21
male (21) 21
oncology (21) 21
cancer (18) 18
middle aged (18) 18
adult (15) 15
chemotherapy (15) 15
colorectal cancer (15) 15
metastasis (13) 13
care and treatment (12) 12
colorectal neoplasms - drug therapy (12) 12
survival (12) 12
analysis (11) 11
fluorouracil (11) 11
treatment outcome (10) 10
colorectal neoplasms - pathology (9) 9
aged, 80 and over (8) 8
bevacizumab (8) 8
disease-free survival (8) 8
irinotecan (8) 8
research (8) 8
capecitabine (7) 7
colorectal neoplasms - genetics (7) 7
follow-up studies (7) 7
leucovorin (7) 7
metastases (7) 7
prognosis (7) 7
5-fluorouracil (6) 6
antineoplastic combined chemotherapy protocols - therapeutic use (6) 6
colorectal carcinoma (6) 6
medicine & public health (6) 6
neoplasm metastasis (6) 6
surgery (6) 6
therapy (6) 6
1st-line treatment (5) 5
antimitotic agents (5) 5
antineoplastic agents (5) 5
antineoplastic agents - therapeutic use (5) 5
camptothecin - analogs & derivatives (5) 5
cancer therapies (5) 5
drug therapy (5) 5
elderly (5) 5
health aspects (5) 5
hematology, oncology and palliative medicine (5) 5
medical prognosis (5) 5
mutation (5) 5
patients (5) 5
radiotherapy (5) 5
trial (5) 5
tumors (5) 5
antibodies, monoclonal - administration & dosage (4) 4
antineoplastic combined chemotherapy protocols - administration & dosage (4) 4
camptothecin - administration & dosage (4) 4
cancer patients (4) 4
dosage and administration (4) 4
fluorouracil - administration & dosage (4) 4
kaplan-meier estimate (4) 4
leucovorin - administration & dosage (4) 4
neoadjuvant therapy (4) 4
neoplasm staging (4) 4
organoplatinum compounds - administration & dosage (4) 4
oxaliplatin (4) 4
patient outcomes (4) 4
rectal neoplasms - therapy (4) 4
surgical oncology (4) 4
toxicity (4) 4
aged patients (3) 3
antibodies, monoclonal, humanized - administration & dosage (3) 3
antineoplastic agents - administration & dosage (3) 3
antineoplastic combined chemotherapy protocols - adverse effects (3) 3
cetuximab (3) 3
chemoradiotherapy (3) 3
clinical trials as topic (3) 3
colorectal neoplasms - mortality (3) 3
diagnosis (3) 3
gastroenterology & hepatology (3) 3
genetic aspects (3) 3
genotype (3) 3
immunology (3) 3
italy (3) 3
management (3) 3
metastatic colorectal cancer (3) 3
monoclonal antibodies (3) 3
mortality (3) 3
neutropenia (3) 3
open-label (3) 3
panitumumab (3) 3
pharmacogenetics (3) 3
pharmacology & pharmacy (3) 3
phase-ii (3) 3
polymorphism, single nucleotide (3) 3
progression-free survival (3) 3
proto-oncogene proteins b-raf - genetics (3) 3
retrospective studies (3) 3
single-nucleotide polymorphism (3) 3
survival rate (3) 3
temozolomide (3) 3
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 6, pp. 738 - 746
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 13, pp. 1306 - 1315
Summary Background In the TRIBE study, FOLFOXIRI (fluorouracil, leucovorin, oxaliplatin, and irinotecan) plus bevacizumab significantly improved... 
Hematology, Oncology and Palliative Medicine | TRIAL | CETUXIMAB | SURROGATE | LEUCOVORIN | ONCOLOGY | END-POINT | PROGRESSION-FREE SURVIVAL | RAS MUTATIONS | GUIDELINES | KRAS | FLUOROURACIL | Leucovorin - administration & dosage | ras Proteins - genetics | Proto-Oncogene Proteins p21(ras) | Bevacizumab - therapeutic use | Bevacizumab - adverse effects | Colorectal Neoplasms - genetics | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Angiogenesis Inhibitors - administration & dosage | Neoplasm Metastasis | Organoplatinum Compounds - administration & dosage | Fluorouracil - administration & dosage | Time Factors | DNA Mutational Analysis | Colorectal Neoplasms - drug therapy | Angiogenesis Inhibitors - therapeutic use | Camptothecin - administration & dosage | Female | Angiogenesis Inhibitors - adverse effects | Camptothecin - analogs & derivatives | Colorectal Neoplasms - mortality | Bevacizumab - administration & dosage | Drug Administration Schedule | Kaplan-Meier Estimate | Proportional Hazards Models | Proto-Oncogene Proteins - genetics | Treatment Outcome | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Proto-Oncogene Proteins B-raf - genetics | Intention to Treat Analysis | Italy | Aged | Infusions, Intravenous | Mutation | Colorectal Neoplasms - pathology | Antimitotic agents | Cancer patients | Care and treatment | Patient outcomes | Analysis | Colorectal cancer | Leucovorin | Metastasis | Antineoplastic agents
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 5, pp. 499 - 508
Journal Article
PLoS ONE, ISSN 1932-6203, 03/2018, Volume 13, Issue 3, p. e0193640
Journal Article
Pharmacogenomics Journal, ISSN 1470-269X, 09/2018, Volume 18, Issue 5, pp. 623 - 632
Journal Article
DIGESTIVE AND LIVER DISEASE, ISSN 1590-8658, 12/2019, Volume 51, Issue 12, pp. 1713 - 1719
Background: Recent data suggest a potential activity and a good tolerability of capecitabine in advanced hepatocellular carcinoma (HCC). Aims: To evaluate... 
MANAGEMENT | Capecitabine | Hepatocellular carcinoma | SORAFENIB | METRONOMIC CHEMOTHERAPY | Systemic therapy | ORAL FLUOROPYRIMIDINE CARBAMATE | 5-FLUOROURACIL | 2ND-LINE TREATMENT | DOUBLE-BLIND | 1ST-LINE THERAPY | GASTROENTEROLOGY & HEPATOLOGY | CLINICAL-PRACTICE | EPIDEMIOLOGY
Journal Article
European Journal of Cancer, ISSN 0959-8049, 2017, Volume 77, pp. 13 - 20
Journal Article
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 10/2014, Volume 371, Issue 17, pp. 1609 - 1618
In patients with metastatic colon cancer, fluorouracil, oxaliplatin, and irinotecan plus bevacizumab, as compared with fluorouracil and irinotecan plus... 
1ST-LINE TREATMENT | MEDICINE, GENERAL & INTERNAL | INFUSIONAL FLUOROURACIL | LEUCOVORIN | MANAGEMENT | PHASE-III | GUIDELINES | IRINOTECAN | OXALIPLATIN | CHEMOTHERAPY | FOLFIRI | Follow-Up Studies | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Bevacizumab | Fluorouracil - therapeutic use | Antibodies, Monoclonal, Humanized - administration & dosage | Leucovorin - adverse effects | Fluorouracil - adverse effects | Neoplasm Metastasis - drug therapy | Colorectal Neoplasms - drug therapy | Adult | Female | Leucovorin - therapeutic use | Liver Neoplasms - secondary | Camptothecin - analogs & derivatives | Colorectal Neoplasms - mortality | Antibodies, Monoclonal, Humanized - adverse effects | Camptothecin - adverse effects | Camptothecin - therapeutic use | Kaplan-Meier Estimate | Liver Neoplasms - drug therapy | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged | Colorectal Neoplasms - pathology | Organoplatinum Compounds - therapeutic use | Organoplatinum Compounds - adverse effects | Treatment outcome | Care and treatment | Analysis | Colorectal cancer | Dosage and administration | Leucovorin | Fluorouracil | Colorectal carcinoma | Diarrhea | Metastasis | Survival | Patients | Clinical outcomes | Metastases | Irinotecan | Stomatitis | Chemotherapy | Neurotoxicity | Oxaliplatin | Monoclonal antibodies | Vascular endothelial growth factor | Neutropenia | Index Medicus | Abridged Index Medicus
Journal Article
Journal Article
Journal Article